Drug
Poziotinib clinical trials
Also written HM781-36B and NOV120101.
Includes 2 studies of Poziotinib hydrochloride.
- studies test it
- 21
- open now
- 0
- in phase 3
- 1
- first study started
- 2009
How studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
21 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 16
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 9
Spectrum Pharmaceuticals, Inc (7) · Hanmi Pharmaceutical Company Limited (5) · National OncoVenture (2) · M.D. Anderson Cancer Center (2) · Yonsei University (2) · Seoul National University Hospital (1) · Samsung Medical Center (1) · Korean Association for the Study of Targeted Therapy (1)
Often tested with
Tested in the same studies.
Alpelisib (1) · Nintedanib (1) · Abemaciclib (1) · Durvalumab (1) · Tremelimumab (1) · Paclitaxel (1) · Trastuzumab (1) · Ado-Trastuzumab Emtansine (1)
Studies
Open first, then newest update. How each study uses poziotinib is read from its arms, and is right about nine times in ten.
Testing it · 21
- A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 MutationsSuspendedPhase 3Spectrum Pharmaceuticals, IncNCT05378763Written as Poziotinib
- A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to PoziotinibTerminatedPhase 2Spectrum Pharmaceuticals, IncNCT03744715Written as Poziotinib
- Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion MutationTerminatedPhase 2Spectrum Pharmaceuticals, IncNCT03318939Written as Poziotinib
- Poziotinib in EGFR Exon 20 Mutant Advanced NSCLCTerminatedPhase 2M.D. Anderson Cancer CenterNCT03066206Written as Poziotinib
- A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced MalignanciesTerminatedPhase 2Spectrum Pharmaceuticals, IncNCT04172597Written as Poziotinib Hydrochloride
- Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung CancerWithdrawnPhase 2M.D. Anderson Cancer CenterNCT05045404Written as Poziotinib Hydrochloride
- Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]CompletedPhase 2Seoul National University HospitalNCT03292250Written as Poziotinib
- Study of Poziotinib in Participants With HER2-Positive Metastatic Breast CancerCompletedPhase 2Spectrum Pharmaceuticals, IncNCT02659514Written as Poziotinib
- Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed RegimensCompletedPhase 2Hanmi Pharmaceutical Company LimitedNCT02418689Written as NOV120101 (Poziotinib)
- Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male SubjectsCompletedPhase 1Spectrum Pharmaceuticals, IncNCT04436562Written as [14C]-Poziotinib
- A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast CancerTerminatedPhase 1Spectrum Pharmaceuticals, IncNCT03429101Written as Poziotinib
- Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion MutationTerminatedPhase 2Hanmi Pharmaceutical Company LimitedNCT04044170Written as Poziotinib
- A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR PathwayCompletedPhase 2Samsung Medical CenterNCT02544997Written as Poziotinib
- Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing TherapyStatus unknownPhase 2Yonsei UniversityNCT02216916Written as HM781-36B
- A Trial to Evaluate the Efficacy of Poziotinib, Pan HER Inhibitor in Recurrent/Metastatic Esophageal Cancer (R/M ESCC)Status unknownPhase 2Yonsei UniversityNCT03770988Written as Treatment with Poziotinib
- Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)CompletedPhase 2Korean Association for the Study of Targeted TherapyNCT02979821Written as Poziotinib
- A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric CancerCompletedPhase 1/2Hanmi Pharmaceutical Company LimitedNCT01746771Written as HM781-36B(Poziotinib)
- NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung AdenocarcinomaTerminatedPhase 2National OncoVentureNCT01819428Written as NOV120101 (Poziotinib)
- NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase InhibitorsCompletedPhase 2National OncoVentureNCT01718847Written as NOV120101 (Poziotinib)
- Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid TumorsCompletedPhase 1Hanmi Pharmaceutical Company LimitedNCT01455571Written as HM781-36B
See all 21 studies that test poziotinib →
Given in every arm · 1 — poziotinib is usual care beside what is tested
Codes
What other systems call poziotinib · ClinicalTrials.gg INT005794
- UNII (FDA) OEI6OOU6IKPOZIOTINIBConfirmed FDA, Wikidata
- Wikidata Q27088426poziotinibConfirmed FDA, Wikidata
- NCI Thesaurus C98838PoziotinibOne source FDA
- DrugBank DB12114One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | OEI6OOU6IK | POZIOTINIB | Confirmed FDA, Wikidata |
| Wikidata | Q27088426 | poziotinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C98838 | Poziotinib | One source FDA |
| DrugBank | DB12114 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.